New way to deliver chemo for stomach cancer shows promise in early trial
NCT ID NCT04220827
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study involves 27 participants and aims to find the highest safe dose while monitoring side effects. If successful, this approach could offer a more targeted treatment option for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- paclitaxel
- What this could lead to
- If successful, this could lead to a safer, more effective way to deliver chemotherapy directly to the abdomen for advanced gastric cancer patients.
- What could go wrong
- This is a very early phase I trial with only 27 participants, so the main goal is safety, not effectiveness. The cancer is advanced and hard to treat, so even if the drug is safe, it may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV GASTRIC CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Lab-Grown tumor models predict the best therapy for each patient?
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- Experimental drug combo targets Hard-to-Treat GI cancers
- New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
- Light-Activated therapy shows promise for tumor control without surgery